Cochrane Review: Cannabinoids for Epilepsy
Cannabinoids for Epilepsy
Four randomized controlled trial reports that included a total of 48 patients, each of which used cannabidiol as the treatment agent. One report was an abstract and another was a letter to the editor. Anti-epileptic drugs were continued in all studies. Details of randomization were not included in any study report. There was no investigation of whether the control and treatment participant groups were the same or different. All the reports were low quality. The four reports only answered the secondary outcome about adverse effects. None of the patients in the treatment groups suffered adverse effects. All the studies were considerably underpowered and had methodologic problems, including the lack of blinding. Two studies showed a reduction in the number of seizures in patients treated with cannabidiol, whereas the other two studies showed no effect.
Source: The Cochrane Review
Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014; 3: CD009270.
Cochrane Database Syst Rev. 2014 Mar 5;(3):CD009270. doi:10.1002/14651858.CD009270.pub3.